ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 1518 • ACR Convergence 2021

    Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study

    Pankti Reid1, David Liew2, Rajshi Akruwala3, Anne Bass4 and Karmela Kim Chan5, 1University of Chicago Medical Center, Chicago, IL, 2Austin Health, Heidelberg, Australia, 3SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, New York, NY

    Background/Purpose: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for cancer management. ICI toxicities can challenge the ability to safely continue ICI therapy…
  • Abstract Number: 1606 • ACR Convergence 2021

    Telemedicine for Rheumatology Care During the COVID-19 Pandemic: Patient Perceptions and Preferences

    Maria I. Danila1, Kelly Gavigan2, Esteban Rivera2, William Nowell2, Michael George3, Jeffrey Curtis4, Lisa Christopher-Stine5, Shubhasree Banerjee3, Peter Merkel3, Kalen Young6, Dianne Shaw6, Jennifer Gordon6 and Shilpa Venkatachalam2, 1University of Alabama at Birmingham, Birmingham, AL, 2Global Healthy Living Foundation, Upper Nyack, NY, 3University of Pennsylvania, Philadelphia, PA, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 5Johns Hopkins University, Baltimore, MD, 6Vasculitis Foundation, Kansas City, MO

    Background/Purpose: The COVID-19 pandemic disrupted the delivery of medical care and resulted in a substantial uptake in telemedicine care for patients with chronic conditions, including…
  • Abstract Number: 1769 • ACR Convergence 2021

    BMS-986256, an Oral Novel Toll-like Receptor 7 and 8 (TLR7/8) Inhibitor, Does Not Affect the Pharmacokinetics of Mycophenolate Mofetil in Healthy Subjects

    Manoj Chiney1, Ihab Girgis2, Melanie Harrison1, Xiaoping Zhang1, Yun Shen3, Michelle Dawes1, Lixian Dong2, Diane Shevell3, Urvi Aras1 and Bindu Murthy3, 1Bristol Myers Squibb, Lawrenceville, NJ, 2Bristol Myers Squibb, Princeton, NJ, 3Bristol Myers Squibb, Lawrenceville

    Background/Purpose: Toll like receptor (TLR) 7 and TLR8 are activated as part of the disease pathophysiology of systemic lupus erythematosus (SLE), including lupus nephritis (LN),…
  • Abstract Number: 0035 • ACR Convergence 2020

    Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides

    Loqmane Seridi1, Matteo Cesaroni1, Qingxuan Song2, Ashley Orillion1, Frédéric Baribaud1, Tatiana Ort1, Sheng Gao2, Tomas Parker3, James Chevalier3, Dan Levine3, Alan Perlman3 and Jarrat Jordan1, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, 3The Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University New York, NY, USA., New York, NY

    Background/Purpose: Approximately 40% of SLE patients will develop Lupus Nephritis (LN), of which 10-30 % will progress to end-stage renal disease. To further understand LN…
  • Abstract Number: 0395 • ACR Convergence 2020

    African Ancestry-Specific Variants Regulate TGFB3 Expression in Systemic Sclerosis

    Julia Hartman1, Andrea Conte2, Chloe Borden3, Urvashi Kaundal4, Yongbing Zhao2, Sarah Safran5, Ami Shah6, Maureen Mayes7, Ayo Doumatey8, Amy Bentley9, Daniel Shriner8, Robyn Domsic10, Thomas Medsger11, Paula Ramos12, Richard Silver13, Virginia Steen14, John Varga15, Vivien Hsu16, Lesley Ann Saketkoo17, Elena Schiopu18, Dinesh Khanna19, Jessica Gordon20, Lindsey Criswell21, Heather Gladue22, Chris Derk23, Elana Bernstein24, S. Louis Bridges25, Victoria Shanmugam26, Kathleen Kolstad27, Lorinda Chung28, Suzanne Kafaja29, Reem Jan30, Marcin Trojanowski31, Avram Goldberg32, Benjamin Korman33, Monique Hinchcliff34, Settara Chandrasekharappa8, Stefania Dell'Orso3, Adebowale Adeyemo8, Charles Rotimi8, Elaine Remmers35, Fredrick Wigley36, Daniel Kastner35, Francesco Boin37, Rafael Casellas2 and Pravitt Gourh4, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Washington, DC, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, 5National Institute of Arthritis and Musculoskeletal and Skin Diseases, New York, NY, 6Johns Hopkins University School of Medicine, Ellicott City, MD, 7University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 8National Human Genome Research Institute, Bethesda, 9National Human Genome Research Institute (NHGRI), NIH, Bethedsa, MD, 10University of Pittsburgh School of Medicine, Pittsburgh, PA, 11University of Pittsburgh School of Medicine, Verona, PA, 12Medical University of South Carolina, Charleston, SC, 13Medical University of South Carolina, Charleston, 14Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 15Northwestern University, Chicago, IL, 16Rutgers-RWJ Medical School, South Plainfield, NJ, 17Scleroderma Patient Care and Research Center, Tulane University, New Orleans, LA, 18Michigan Medicine, Ann Arbor, MI, 19University of Michigan, Ann Arbor, MI, 20Hospital for Special Surgery, New York, NY, 21Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, CA, 22Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, 23University of Pennsylvania, Philadelphia, PA, 24Columbia University, New York, NY, 25University of Alabama at Birmingham, Mountain Brk, AL, 26The George Washington University, Washington, DC, 27Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 28Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, 29David Geffen School of Medicine, UCLA, Los Angeles, CA, 30Pritzker School of Medicine, University of Chicago, Chicago, IL, 31Boston University Medical Center, BOSTON, MA, 32NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, 33Department of Medicine, University of Rochester Medical Center, Rochester, NY, 34Yale School of Medicine, Westport, CT, 35National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, 36Johns Hopkins University School of Medicine, Baltimore, MD, 37University of California San Francisco, Cedars-Sinai, West Hollywood, CA

    Background/Purpose: African American (AA) patients have a higher prevalence of SSc than European Americans (EA). Adding to this health disparity, AA SSc patients are more…
  • Abstract Number: 0595 • ACR Convergence 2020

    High Satisfaction with Tele-medicine in a New York City Clinic

    Tommy Chen1, Cathy Guo1, Wei Tang1, Leila Khalili1 and Anca Askanase2, 1Columbia University Medical Center, New York, NY, 2Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose: The face of medicine is changing with the time. A twenty-first century technological revolution in medicine happened in March 2020 as the COVID-19 pandemic…
  • Abstract Number: 0862 • ACR Convergence 2020

    Voclosporin Does Not Decrease Mycophenolic Acid Concentrations in Patients with SLE

    Teun van Gelder1, Robert Huizinga2, Neil Solomons2 and Laura Lisk3, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc., Victoria, BC, Canada

    Background/Purpose: Voclosporin (VCS) is a novel calcineurin inhibitor, structurally similar to cyclosporine A (CsA). In a Phase 3 clinical trial in patients with active lupus…
  • Abstract Number: 1052 • ACR Convergence 2020

    Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska

    Joanna Marco1 and Elizabeth Ferucci2, 1University of Washington, Seattle, WA, 2Alaska Native Tribal Health Consortium, Anchorage, AK

    Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
  • Abstract Number: 1307 • ACR Convergence 2020

    Detecting Subtle Changes in Fundoscopic Retinal Images in Patients with Axial Spondyloarthritis with Deep Learning

    Yun Ju Huang1, Chang-Fu Kuo2, Yu Huei Huang3, Yih Shiou Hwang4 and Chihung Lin5, 1Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan (Republic of China), 2Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China), 3Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), 4Department of Ophthalmology, Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China), 5Chang Gung Memorial Hospital, Taoyuan city, Taiwan (Republic of China)

    Background/Purpose: Fundoscopy is essential to identify the retinopathy of patients with autoimmune diseases. However, the classification of different autoimmune diseases is difficult by human eyes…
  • Abstract Number: 1471 • ACR Convergence 2020

    Healthy Lifestyle and Risk of Rheumatoid Arthritis in Women: A Prospective Cohort Study

    Jill Hahn1, May Choi2, Susan Malspeis3, Emma Stevens4, Elizabeth Karlson4, Kazuki Yoshida5, Laura Kubzansky6, Jeffrey Sparks7 and Karen Costenbader8, 1Brigham and Womens' Hospital, Newton, MA, 2Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital, Boston, 4Brigham and Women's Hospital, Boston, MA, 5Brigham & Women's Hospital and Harvard Medical School, Boston, MA, 6Harvard T.H. Chan School of Public Health, Boston, MA, 7Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 8Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Many potentially modifiable biobehavioral factors have been associated with the risk of developing rheumatoid arthritis (RA), but the benefit of adopting an overall healthy…
  • Abstract Number: 1750 • ACR Convergence 2020

    Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial

    Juergen Rech1, Hannah Schenker2, Koray Tascilar1, Melanie Hagen2, Larissa Valor Mendez2, Verena Schoenau3, Marina Sergeeva4, Jutta Prade4, Mageshvar Sulvakumar5, Laura Konert6, Arnd Kleyer1, David Simon1, Sandra Strobelt4, Frank Behrens7, Christoph Baerwald8, Stephanie Finzel9, Reinhard Voll10, Axel Hueber11, Eugen Feist12, Julie Roesch13, José A. P. da Silva14, Arnd Doerfler13, Nemanja Damjanov15, Andreas Hess16 and Georg Schett17, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, 4Institute for Experimental Pharmacology, Erlangen, Germany, 5Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, 6Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, 7CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 8Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, 9Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 10Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, 11Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 12Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 13Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 149.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 15Belgrade University School of Medicine, Belgrade, Serbia, 16Institute for Experimental Pharmacology, Erlangen, 17Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
  • Abstract Number: PP05 • ACR Convergence 2020

    Coping Through Advocacy – My Story Living with Relapsing Polychondritis

    Allegonda Imeson1, 1The Canadian Society for Relapsing Polychondritis, Stony Plain, AB, Canada

    Background/Purpose: Becoming a mother was the most pivotal moment of my life. From early on, I instilled the importance of a physical, healthy lifestyle for my two…
  • Abstract Number: 0037 • ACR Convergence 2020

    Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome

    Adrianos Nezos1, Eleni Kotsifaki1, Charalampos Skarlis2, Konstantinos Markakis1, Haralampos Moutsopoulos3, Michael Koutsilieris1, Clio Mavragani1 and Anna Psarrou1, 1National & Kapodistrian University of Athens, Athens, Greece, 2National &Kapodistrian University of Athens, Athens, Greece, 3National & Kapodistrian University of Athens/ Academy of Athens, Athens, Greece

    Background/Purpose: B-cell non-Hodgkin's lymphoma (B-NHL) is one of the major complications of primary Sjögren’s syndrome (SS). Chronic inflammation and macrophages in SS minor salivary glands…
  • Abstract Number: 0417 • ACR Convergence 2020

    Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

    Eduardo Martin-Nares1, Janette Furuzawa-Carballeda1, Ángel Alexis Priego-Ranero1, Isela Chan-Campos1, Gladys Sulikey Herrera-Noguera1, Fidel López-Verdugo1 and Gabriela Hernandez-Molina1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Patients with IgG4-related disease (IgG4-RD) can be classified in clinical phenotypes which differ in terms of demographics, clinical and serological features. Whether there are…
  • Abstract Number: 0606 • ACR Convergence 2020

    A Systematic Review Exploring Pre-COVID-19 Telehealthcare Models Used in the Management of Patients with Rheumatological Disease

    Alexandra Nelson1 and Marina Anderson2, 1University of Liverpool, Liverpool, United Kingdom, 2Lancaster University, Lancaster, United Kingdom

    Background/Purpose: Recent advancements in the delivery and utilization of information and communication technologies (ICTs) have led to an increased application of telehealthcare services. Global coronavirus…
  • « Previous Page
  • 1
  • …
  • 58
  • 59
  • 60
  • 61
  • 62
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology